VAISITTI, Tiziana
 Distribuzione geografica
Continente #
NA - Nord America 3.972
EU - Europa 2.881
AS - Asia 2.159
SA - Sud America 234
AF - Africa 99
OC - Oceania 6
Totale 9.351
Nazione #
US - Stati Uniti d'America 3.893
IT - Italia 1.072
CN - Cina 939
SG - Singapore 742
DE - Germania 289
IE - Irlanda 270
SE - Svezia 256
BR - Brasile 196
UA - Ucraina 185
AT - Austria 166
FR - Francia 133
FI - Finlandia 132
GB - Regno Unito 107
HK - Hong Kong 78
KR - Corea 78
VN - Vietnam 77
SN - Senegal 65
JP - Giappone 61
CA - Canada 59
PL - Polonia 58
IN - India 49
ES - Italia 44
NL - Olanda 28
BE - Belgio 27
ID - Indonesia 25
CZ - Repubblica Ceca 23
IR - Iran 16
TW - Taiwan 15
CH - Svizzera 14
MX - Messico 14
BY - Bielorussia 13
DK - Danimarca 12
UZ - Uzbekistan 12
CL - Cile 11
RU - Federazione Russa 11
TR - Turchia 11
ZA - Sudafrica 11
EG - Egitto 10
GR - Grecia 8
MO - Macao, regione amministrativa speciale della Cina 8
PH - Filippine 8
AE - Emirati Arabi Uniti 7
AR - Argentina 7
CO - Colombia 7
SA - Arabia Saudita 7
NG - Nigeria 6
RO - Romania 6
AU - Australia 5
EC - Ecuador 4
LT - Lituania 4
LU - Lussemburgo 4
NO - Norvegia 4
PK - Pakistan 4
TH - Thailandia 4
UY - Uruguay 4
BD - Bangladesh 3
EE - Estonia 3
IL - Israele 3
IQ - Iraq 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
VE - Venezuela 3
CR - Costa Rica 2
HU - Ungheria 2
LK - Sri Lanka 2
MA - Marocco 2
NP - Nepal 2
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GH - Ghana 1
GT - Guatemala 1
HR - Croazia 1
KZ - Kazakistan 1
LB - Libano 1
LI - Liechtenstein 1
LV - Lettonia 1
MN - Mongolia 1
MU - Mauritius 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PE - Perù 1
PY - Paraguay 1
TJ - Tagikistan 1
TN - Tunisia 1
Totale 9.351
Città #
Chandler 585
Singapore 397
Beijing 348
Santa Clara 302
Dublin 269
Torino 263
Ashburn 201
Turin 186
Houston 162
Ann Arbor 156
Vienna 146
Nyköping 136
Fairfield 132
Columbus 94
Jacksonville 90
Milan 89
Wilmington 89
Medford 81
Princeton 81
Redwood City 67
Villeurbanne 65
Dearborn 63
Guangzhou 62
Woodbridge 59
Hong Kong 56
Dong Ket 55
Nuremberg 55
Munich 53
Shanghai 52
Centro 50
Cambridge 48
Fremont 48
Boston 47
Seattle 46
Warsaw 46
New York 42
Hefei 37
Hangzhou 35
San Mateo 30
Boardman 29
Nanjing 29
Düsseldorf 28
Helsinki 27
Jakarta 25
Pisa 25
San Diego 25
Los Angeles 24
Turku 21
Brussels 18
Toronto 18
Rome 17
Tokyo 17
Garessio 15
London 15
Seoul 15
Xian 15
The Dalles 14
Silver Spring 13
Wuhan 13
Barcelona 12
Chengdu 12
Novara 12
Rio de Janeiro 12
Shenyang 11
Chicago 10
Falls Church 10
Phoenix 10
Brookline 9
Frankfurt am Main 9
Kunming 9
Madrid 9
San Francisco 9
São Paulo 9
Vestignè 9
Bologna 8
Genoa 8
Hebei 8
Naples 8
Norwalk 8
Perugia 8
Stockholm 8
Taipei 8
Tianjin 8
Austin 7
Detroit 7
Falkenstein 7
Mexico City 7
Ottawa 7
Philadelphia 7
Southampton 7
Wenzhou 7
Zhengzhou 7
Abuja 6
Amsterdam 6
Brooklyn 6
Delhi 6
Edmonton 6
Evanston 6
Hamburg 6
La Jolla 6
Totale 5.561
Nome #
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. 802
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. 554
Mutations in NOTCH1 PEST-domain orchestrate CCL19-driven homing of Chronic Lymphocytic Leukemia cells by modulating the tumor suppressor gene DUSP22 402
Subcellular characterization of NAD+ biosynthesis in metastatic melanoma by using organelle-specific biosensors 357
Clinical exome sequencing is a powerful tool in the diagnostic flow of monogenic kidney diseases: an Italian experience 190
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response 182
Targeting metabolism and survival in chronic lymphocytic leukemia and richter syndrome cells by a novel NF-κB inhibitor 170
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS 147
Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma 147
The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies 142
NAD+-metabolizing ecto-enzymes shape tumor-host interactions: the chronic lymphocytic leukemia model. 139
Immune response dysfunction in chronic lymphocytic leukemia: Dissecting molecular mechanisms and microenvironmental conditions 138
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment 131
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models 131
USE OF CLINICAL EXOME SEQUENCING IN THE DIAGNOSTIC FLOW OF MONOGENIC KIDNEY DISEASES: THE PIEDMONT EXPERIENCE 130
CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells 129
NOVEL AND KNOWN MUTATIONS IDENTIFIED BY CLINICAL EXOME SEQUENCING FOR THE DIAGNOSIS OF POLYCYSTIC KIDNEY DISEASE 124
Nampt over-expression recapitulates the braf inhibitor resistant phenotype plasticity in melanoma 123
Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis 122
Abstract 5170: Metabolism and cancer: The CD38-NAMPT connection in chronic lymphocytic leukemia 121
Adult-onset CblC deficiency: a challenging diagnosis involving different adult clinical specialists 119
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment 118
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death 116
B Cell Receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter Transformation 111
CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential 110
CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells 109
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology 108
Abstract 2302: The extracellular form of NAMPT contributes to creating a proinflammatory environment in chronic lymphocytic leukemia 108
Abstract 2630: Nicotinamide activates the p53/miR-34a/SIRT1 tumor suppressor network leading to apoptosis of chronic lymphocytic leukemia cells 108
HLA and AB0 Polymorphisms May Influence SARS-CoV-2 Infection and COVID-19 Severity 108
CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity 107
Chronic lymphocytic leukemia 104
CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival 103
Mutations in NOTCH1 PEST Domain Orchestrate CCL19-Driven Homing of Chronic Lymphocytic Leukemia (CLL) Cells By Modulating the Gene DUSP22 101
Targeting the Adenosinergic Axis in the Eμ-TCL1 Chronic Lymphocytic Leukemia Mouse Model Offers Novel Therapeutic Opportunities 101
Extracellular Nicotinamide Phosphoribosyltransferase (NAMPT) Shapes the CLL Microenvironment Promoting Macrophage M2 Polarization Via a Non-Enzymatic Mechanism 99
CD38 at the junction between prognostic marker and therapeutic target 97
Cationization of monoclonal antibodies: another step towards the 'magic bullet'? 96
Multiple metamorphoses of CD38 from prognostic marker to disease modifier to therapeutic target in chronic lymphocytic leukemia. 96
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy 95
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia 95
HLA-DRB1 mismatch-based identification of donor-derived cell free DNA (dd-cfDNA) as a marker of rejection in heart transplant recipients: A single-institution pilot study. 95
The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. 92
SLAMF1/CD150 Activates Autophagy in Chronic Lymphocytic Leukemia Cells, Modulating Chemotaxis and Responses to Therapy 90
The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. 90
Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia 89
CD38 in chronic lymphocytic leukemia: from bench to bedside? 89
Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. 87
In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia 84
Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia 84
CD38 signals up-regulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells. 83
Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets 83
A novel COLEC10 mutation in a child with 3MC syndrome 83
Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. 81
CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells 80
CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells 80
E2A is a transcriptional regulator of CD38 expression in chroniclymphocytic leukemia 78
The frequency of rare and monogenic diseases in pediatric organ transplant recipients in Italy 78
CD38/CD19: a lipid raft dependent signaling complex in human B cells 77
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 77
Targeting of the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia 75
Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models 74
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. 73
Validation of a Simple, Rapid, and Cost-Effective Method for Acute Rejection Monitoring in Lung Transplant Recipients 72
Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. 72
Novel Approaches for the Treatment of Patients with Richter’s Syndrome 72
Targeting the adenosinergic axis in chronic lymphocytic leukemia: A way to disrupt the tumor niche? 71
CD38/CD31 interactions activate genetic pathways leading toproliferation and migration in chronic lymphocytic leukemia cells 67
Novel richter syndrome xenograft models to study genetic architecture, biology, and therapy responses 63
Nicotinamide Blocks Proliferation and Induces Apoptosis of Chronic Lymphocytic Leukemia Cells through Activation of the p53/miR-34a/SIRT1 Tumor Suppressor Network. 58
Lift the curtain on long non-coding RNAs in hematological malignancies: Pathogenic elements and potential targets 57
Anti-CD37 α-amanitin–conjugated antibodies as potential therapeutic weapons for Richter syndrome 51
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. 51
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild type chronic lymphocytic leukemia. 51
The humoral and cellular response to mRNA SARS-CoV-2 vaccine is influenced by HLA polymorphisms 50
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia 49
Regulation Of CLL Growth and Trafficking By The Enzymatic Functions Of CD38: Implications For Therapeutic Targeting 48
Relevance of next generation sequencing (NGS) data re-analysis in the diagnosis of monogenic diseases leading to organ failure 46
The role of genetic testing in the diagnostic workflow of pediatric patients with kidney diseases: the experience of a single institution 44
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 38
A new taxonomy for splenic marginal zone lymphoma 38
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities 25
Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo 24
A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome 23
Genomic and Transcriptomic Profile of HNF1A-Mutated Liver Adenomas Highlights Molecular Signature and Potential Therapeutic Implications 21
Functional evaluation of a novel nonsense variant of the calcium-sensing receptor gene leading to hypocalcemia 18
Matching clinical and genetic data in pediatric patients at risk of developing cystic kidney disease 15
Technical Advances in Circulating Cell-Free DNA Detection and Analysis for Personalized Medicine in Patients’ Care 15
Complementary approaches define the metabolic features that accompany Richter syndrome transformation 15
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia 14
Circulating cell-free DNA in liver transplantation: A pre- and post-transplant biomarker of graft dysfunction 13
Donor-derived Cell-free DNA Evaluation in Pediatric Heart Transplant Recipients: A Single-center 12-mo Experience 11
Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter’s syndrome 5
Totale 9.609
Categoria #
all - tutte 33.547
article - articoli 0
book - libri 0
conference - conferenze 5.644
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.191


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.186 62 65 49 42 188 75 145 93 176 94 62 135
2021/20221.290 77 59 63 86 73 131 87 65 55 131 288 175
2022/20231.672 174 182 38 172 119 368 104 113 196 67 78 61
2023/2024980 109 154 57 37 92 114 41 100 21 60 87 108
2024/20252.556 46 146 84 238 510 215 88 125 379 177 221 327
2025/202689 89 0 0 0 0 0 0 0 0 0 0 0
Totale 9.609